Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-05-06

Clinical Trial Update: Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing intravitreal aflibercept to laser therapy for retinopathy of prematurity has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aflibercept (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Retinopathy of Prematurity (ROP) | Phase 3 | Status: COMPLETED | Results posted: 2022-05-06